Detailed Abstract
[E-poster - Liver (Liver Disease/Surgery)]
[EP 016] SYSTEMIC INTRAVENOUS INFUSION OF THE CHORIONIC PLATE MESENCHYMAL STEM CELLS MAY STABILIZE THE DECOMPENSATION OF LIVER CIRRHOSIS
Denis EFIMOV 1, Ekaterina PETROVSKAYA 2, Dzianis SADOUSKI 1, Ekaterina NAZAROVA 2, Evgeniya PRIMAKOVA 2, Ala SYMANOVICH 2, Natalyia DEDYULYA 2, Sergey KOROTKOV 1, Aliaksei SHCHERBA 1, Svetlana KRIVENKO 2, Oleg RUMMO 1
1 Transplantation, Minsk Scientific And Practical Center for Surgery, Transplantology And Hematology, BELARUS, 2 Cell Biotechnology , Minsk Scientific And Practical Center for Surgery, Transplantology And Hematology, BELARUS
Background : Placental mesenchymal stem cells (MSC) possess multipotency and remarkable immunomodulatory features with robust and constitutive anti-inflammatory and anti-fibrotic properties, making them suitable for the treatment of different acute and chronic liver disorders. The aim of this study was to evaluate the safety and therapeutic potential of systemic intravenous chorionic plate (CP) MSC infusion for the treatment of decompensated liver cirrhosis.
Methods : We report an experience of 12 prospective clinical cases (age – 43 (28-67); MELD – 27 (11-35)) of intravenous systemic CP MSC infusion (~2 mln per kg) in decompensated liver cirrhosis patients. Inclusion criteria: age under 18, total bilirubin >100 mmol/l, cirrhosis decompensation, inpatient treatment demand. CP MSC were obtained from the placenta of a healthy woman in labour.
Results : Neither side effects nor other complications were observed. The significant decrease in total bilirubin by 133 mmol/l (39%) from the maximum level was registered during 1st week after infusion, as well as stabilization of coagulopathy (INR decrease by 0.37 (25%)). In 3 cases liver transplantation (LT) was performed (during 1st month after; 100% survival). 1 patient deceased due to severe variceal bleeding (on the 8th day after). In 8 patients, decompinsation stabilization was observed, which made possible to continue treatment at the outpatient stage, two patients subsequently underwent LT (2 and 6 months after), 1 patient (8%) deceased due to severe pnemonia on the waiting list (8 months after).
Conclusions : Intravenous CP MSC infusion may stabilize the decompensation of liver cirrhosis and serve as a bridge for the liver transplantation.
Methods : We report an experience of 12 prospective clinical cases (age – 43 (28-67); MELD – 27 (11-35)) of intravenous systemic CP MSC infusion (~2 mln per kg) in decompensated liver cirrhosis patients. Inclusion criteria: age under 18, total bilirubin >100 mmol/l, cirrhosis decompensation, inpatient treatment demand. CP MSC were obtained from the placenta of a healthy woman in labour.
Results : Neither side effects nor other complications were observed. The significant decrease in total bilirubin by 133 mmol/l (39%) from the maximum level was registered during 1st week after infusion, as well as stabilization of coagulopathy (INR decrease by 0.37 (25%)). In 3 cases liver transplantation (LT) was performed (during 1st month after; 100% survival). 1 patient deceased due to severe variceal bleeding (on the 8th day after). In 8 patients, decompinsation stabilization was observed, which made possible to continue treatment at the outpatient stage, two patients subsequently underwent LT (2 and 6 months after), 1 patient (8%) deceased due to severe pnemonia on the waiting list (8 months after).
Conclusions : Intravenous CP MSC infusion may stabilize the decompensation of liver cirrhosis and serve as a bridge for the liver transplantation.
SESSION
E-poster
E-Session 03/21 ALL DAY